Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Subclinical atherosclerosis burden predicts cardiovascular events in individuals with diabetes and chronic kidney disease

  • Palanca, Ana
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Betriu, Àngels|||0000-0002-0290-4586
  • Perpiñán, Hèctor
  • Soldevila i Madorell, Berta|||0000-0002-4582-4201
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Groop, Per-Henrik
  • Fernández, Elvira|||0000-0001-5236-1762
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
Individuals with diabetes have remarkably high rates of cardiovascular morbidity and mortality. However, the incremental cardiovascular risk in diabetes is heterogeneous and has often been related to renal involvement. The purpose of this study was to analyse the prognostic value of subclinical atherosclerosis in determining the incidence of first cardiovascular events (CVEs) in individuals with diabetes and chronic kidney disease (CKD) compared to CKD individuals without diabetes. We included data from individuals with CKD with and without diabetes, free from pre-existing cardiovascular disease, from the NEFRONA cohort. Participants underwent baseline carotid and femoral ultrasound and were followed up for 4 years. All CVEs during follow-up were registered. Bivariate analysis and Fine-Gray competing risk models were used to perform the statistical analysis. During the mean follow-up time of 48 months, a total of 203 CVE was registered. 107 CVE occurred among participants without diabetes (19.58 per 1000 person-years) and 96 CVE occurred among participants with diabetes (44.44 per 1000 person-years). Following the competing risk analysis, the variables predicting CVEs in CKD individuals without diabetes were the number of territories with plaque at baseline (HR 1.862, 95% CI [1.432;2.240]), age (HR 1.026, 95% CI [1.003;1.049]) and serum concentrations of 25-OH vitamin D (HR 0.963, 95% CI [0.933;0.094]). The only variable predicting CVEs among CKD participants with diabetes was the number of territories with plaque at baseline (HR 1.782, 95% CI [1.393, 2.278]). For both models, concordance (C) index yielded was over 0.7. The burden of subclinical atherosclerosis is the strongest predictor of future CVEs in diabetic individuals with CKD. Early detection of subclinical atherosclerotic burden by multiterritorial vascular ultrasound could improve CVE prediction in this population. The online version of this article (10.1186/s12933-019-0897-y) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of the Scavenger Receptor CD36 in Accelerated Diabetic Atherosclerosis

  • Navas Madroñal, Miquel|||0000-0003-2984-1471
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Consegal, Marta|||0000-0002-9201-9117
  • Ramírez-Morros, Anna|||0000-0001-8263-1292
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Perez, Paulina
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Galán, María|||0000-0002-4758-8388
  • Mauricio, Didac|||0000-0002-2868-0250
Diabetes mellitus entails increased atherosclerotic burden and medial arterial calcification, but the precise mechanisms are not fully elucidated. We aimed to investigate the implication of CD36 in inflammation and calcification processes orchestrated by vascular smooth muscle cells (VSMCs) under hyperglycemic and atherogenic conditions. We examined the expression of CD36, pro-inflammatory cytokines, endoplasmic reticulum (ER) stress markers, and mineralization-regulating enzymes by RT-PCR in human VSMCs, cultured in a medium containing normal (5 mM) or high glucose (22 mM) for 72 h with or without oxidized low-density lipoprotein (oxLDL) (24 h). The uptake of 1,1'-dioctadecyl-3,3,3',3-tetramethylindocarbocyanine perchlorate-fluorescently (DiI) labeled oxLDL was quantified by flow cytometry and fluorimetry and calcification assays were performed in VSMC cultured in osteogenic medium and stained by alizarin red. We observed induction in the expression of CD36, cytokines, calcification markers, and ER stress markers under high glucose that was exacerbated by oxLDL. These results were confirmed in carotid plaques from subjects with diabetes versus non-diabetic subjects. Accordingly, the uptake of DiI-labeled oxLDL was increased after exposure to high glucose. The silencing of CD36 reduced the induction of CD36 and the expression of calcification enzymes and mineralization of VSMC. Our results indicate that CD36 signaling is partially involved in hyperglycemia and oxLDL-induced vascular calcification in diabetes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease

  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Sarrias, Maria R.
  • Betriu, Àngels|||0000-0002-0290-4586
  • Barranco-Altirriba, Maria|||0000-0002-1525-210X
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Groop, Per-Henrik
  • Fernández, Elvira|||0000-0001-5236-1762
  • Mauricio, Didac|||0000-0002-2868-0250
This study assessed the association of CD5L and soluble CD36 (sCD36) with the risk of a cardiovascular event (CVE), including CV death and all-cause mortality in CKD. We evaluated the association of CD5L and sCD36 with a predefined composite CV endpoint (unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular accident, congestive heart failure, arrhythmia, peripheral arterial disease [PAD] or amputation by PAD, aortic aneurysm, or death from CV causes) and all-cause mortality using Cox proportional hazards regression, adjusted for CV risk factors. The analysis included 1,516 participants free from pre-existing CV disease followed up for 4 years. The median age was 62 years, 38.8% were female, and 26.8% had diabetes. There were 98 (6.5%) CVEs and 72 (4.8%) deaths, of which 26 (36.1%) were of CV origin. Higher baseline CD5L concentration was associated with increased risk of CVE (HR, 95% CI, 1.17, 1.0-1.36), and all-cause mortality (1.22, 1.01-1.48) after adjusting for age, sex, diabetes, systolic blood pressure, dyslipidemia, waist circumference, smoking, and CKD stage. sCD36 showed no association with adverse CV outcomes or mortality. Our study showed for the first time that higher concentrations of CD5L are associated with future CVE and all-cause mortality in individuals with CKD.